Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Pituitary Neoplasms 1Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 10Everolimus 5lanreotide 4gallium Ga 68 dotatate 4Nivolumab 4Magnetic Resonance Spectroscopy 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3Temozolomide 3Somatostatin 3Capecitabine 3surufatinib 2pembrolizumab 2copper dotatate CU-64 2cabozantinib 2amino-acid, glucose, and electrolyte solution 2Specimen Handling 2Octreotide 2Lutetium-177 2Lutetium 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2tivozanib 1talazoparib 1sintilimab 1repotrectinib 1lenvatinib 1guarana powder 1gadoteridol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroendocrine Tumors × Critical Pathways × Clear all
NCT06015802 2023-08-29

Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors

Sun Yat-sen University

Recruiting
300 enrolled
EndocrineNET

Pituitary Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡